Other promising targets that have been developed and are under clinical trial validation to treat hematological malignancies are CD33 and CD123 for acute myeloid leukemia (AML), CD133 for AML and ALL, CD138 and BMCA for multiple myeloma (MM), the immunoglobulin Kappa chain (Igκ) for CLL, and inactive tyrosine-protein kinase transmembrane receptor (ROR1) for CLL and ALL (Carpenter et al., 2013; Finney et al., 1998; Hudecek et al., 2010; Mardiros et al., 2013; Vera et al., 2006; Zhu et al., 2015). Here, PROM1 is linked to acute lymphoblastic leukemia.